MLYS

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-23-000061 · wf-form4_169179546088184.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,040,318

F1 · price: The price reported is the weighted-average purchase price, purchased in multiple transactions at prices ranging from $12.8522 to $12.9257. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · derivative · entry 7

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,202

Underlying: Common Stock · 74,625 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported is the weighted-average sales price, sold in multiple transactions at prices ranging from $13.00 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

SEC source: 0001933414-23-000062 · wf-form4_169179547763057.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-23-000043 · wf-form4_168933930313513.xml · derivative · entry 2

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 88,000

Underlying: Common Stock · 88,000 shares

Expires 2033-02-09

F3 · kind: Represents stock options transferred pursuant to option transfer agreements between Catalys Pacific Fund, LP and each of Brian Taylor Slingsby and Takeshi Takahashi.

F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

F4 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001933414-23-000043 · wf-form4_168933930313513.xml · derivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between Brian Taylor Slingsby and Catalys Pacific Fund, LP.

F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001933414-23-000044 · wf-form4_168933932048702.xml · derivative · entry 1

Takahashi Takeshi · CIK 0001963933 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001933414-23-000026 · wf-form4_168297155965134.xml · derivative · entry 1

Litzka Olivier · CIK 0001963940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · kind: Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and BioDiscovery 6 FCPI.

F2 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001933414-23-000020 · wf-form4_167943885949772.xml · derivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-03-17

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001933414-23-000022 · wf-form4_167943889214123.xml · derivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-03-17

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001933414-23-000021 · wf-form4_167943887821849.xml · derivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,800

Underlying: Common Stock · 99,800 shares

Expires 2033-03-17

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001628280-23-003924 · wf-form4_167658446540333.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO, Chief Bus. Off. and Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,811

SEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · derivative · entry 5

HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 964,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.

F2 · derivative.exercise_date: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.

F2 · derivative.expiration_date: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.

SEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · derivative · entry 4

HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,941,368 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.

SEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · nonDerivative · entry 3

HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,218,106

SEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · nonDerivative · entry 2

HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,905,606

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.

SEC source: 0001104659-23-022971 · tm235636-2_4seq1.xml · nonDerivative · entry 1

HBM Healthcare Investments (Cayman) Ltd. · CIK 0001232258 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,941,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.

SEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · derivative · entry 4

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,446,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · derivative · entry 3

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,135,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · nonDerivative · entry 2

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,519,361

F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001628280-23-003923 · wf-form4_167658444611991.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,581,861

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001104659-23-022868 · tm237178-1_4.xml · derivative · entry 6

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 192,847 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and Nexus Fund III. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Fund III. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4 · ownership.nature: Shares are held directly by the Fund.

SEC source: 0001104659-23-022868 · tm237178-1_4.xml · derivative · entry 5

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,735,629 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Shares are held directly by RA Capital Nexus Fund III, L.P. (the "Nexus Fund III").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and Nexus Fund III. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Fund III. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-23-022868 · tm237178-1_4.xml · nonDerivative · entry 4

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,311,247

F4 · balance_after: Shares are held directly by the Fund.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and Nexus Fund III. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Fund III. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4 · ownership.nature: Shares are held directly by the Fund.

SEC source: 0001104659-23-022868 · tm237178-1_4.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 192,847

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F4 · balance_after: Shares are held directly by the Fund.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and Nexus Fund III. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Fund III. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4 · ownership.nature: Shares are held directly by the Fund.

SEC source: 0001104659-23-022868 · tm237178-1_4.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,867,229

F2 · balance_after: Shares are held directly by RA Capital Nexus Fund III, L.P. (the "Nexus Fund III").

F2 · ownership.nature: Shares are held directly by RA Capital Nexus Fund III, L.P. (the "Nexus Fund III").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and Nexus Fund III. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Fund III. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-23-022868 · tm237178-1_4.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director

RA Capital Healthcare Fund LP · CIK 0001315082 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director

Shah Rajeev M. · CIK 0001619841 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,735,629

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · balance_after: Shares are held directly by RA Capital Nexus Fund III, L.P. (the "Nexus Fund III").

F2 · ownership.nature: Shares are held directly by RA Capital Nexus Fund III, L.P. (the "Nexus Fund III").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and Nexus Fund III. The general partner of RA Capital Management, L.P. is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Fund III. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · derivative · entry 4

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,142,751 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · derivative · entry 3

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,171,342 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · nonDerivative · entry 2

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,194,579

F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-23-003922 · wf-form4_167658442850041.xml · nonDerivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,944,579

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

F2 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-23-003424 · wf-form4_167634007134725.xml · derivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO, Chief Bus. Off. and Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,518

Underlying: Common Stock · 97,518 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001628280-23-003423 · wf-form4_167634004383047.xml · derivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,186

Underlying: Common Stock · 104,186 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001628280-23-003427 · wf-form4_167634012632329.xml · derivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001104659-23-020187 · tm236718-1_4.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2023-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

F2 · ownership.nature: The option was awarded to Dr. Derek DiRocco in connection with his service as a director of the Issuer. Dr. DiRocco is a Partner of RA Capital Management, L.P. (the "Adviser") and, under his arrangement with the Adviser, Dr. DiRocco holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). Dr. DiRocco is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund III to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

F3 · ownership.nature: The Adviser is the investment manager for the Fund and Nexus Fund III. The general partner of the Fund is RA Capital Management GP, LLC (the "Adviser GP"), of which Peter Kolchinsky, Ph.D. and Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held of record by the Fund and Nexus Funds III. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-23-003425 · wf-form4_167634009091121.xml · derivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,046

Underlying: Common Stock · 250,046 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

SEC source: 0001628280-23-003431 · wf-form4_167634020870900.xml · derivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001628280-23-003430 · wf-form4_167634018923335.xml · derivative · entry 1

DiRocco Derek · CIK 0001792061 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001628280-23-003426 · wf-form4_167634010800773.xml · derivative · entry 1

Asam Alexander · CIK 0001801066 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001628280-23-003428 · wf-form4_167634014769384.xml · derivative · entry 1

Litzka Olivier · CIK 0001963940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.

SEC source: 0001628280-23-003429 · wf-form4_167634016642512.xml · derivative · entry 1

Takahashi Takeshi · CIK 0001963933 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2033-02-09

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on March 9, 2023.